SEARCH

SEARCH BY CITATION

References

  • Abi-Gerges N, Philp K, Pollard C, Wakefield I, Hammond TG, Valentin JP (2004). Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam Clin Pharmacol 18: 139151.
  • Anon (1997). Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. London, 17 December 1997. CPMP/986/96. CPMP CPMP/986/96.
  • Anon (2000). ICH S7A Safety pharmacology studies for human pharmaceuticals. London, 16 November 2000. CPMP/ICH/539/00. ICH S7B CPMP/ICH/539/00.
  • Anon (2005a). The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH E14 CHMP/ICH/2/04.
  • Anon (2005b). The nonclinical evaluation of the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. ICH S7B CHMP/ICH/423/02.
  • Belardinelli L, Antzelevitch C, Vos MA (2003). Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 24: 619625.
  • Bischoff U, Schmidt C, Netzer R, Pongs O (2000). Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 406: 341343.
  • Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M et al. (2006). Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 54: 189199.
  • Cavero I, Mestre M, Guillon JM, Crumb W (2000). Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 1: 947973.
  • Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80: 795803.
  • De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 26: 590597.
  • DiMasi JA, Hansen RW, Grabowski HG (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22: 151185.
  • Easter A, Prior HM, Abi-Gerges N, Moors J, Lawrence CL, Philp K et al. (2006). Summary of data emerging from pre-clinical integrated risk assessments. J Pharmacol Toxicol Methods 54: 228.
  • Eisenhauer MD, Eliasson AH, Taylor AJ, Coyne PE Jr, Wortham, DC (1994). Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 105: 389395.
  • Gavaghan CL, Arnby CH, Blomberg N, Strandlund G, Boyer S (2007). Development, interpretation and temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput Aided Mol Des 21: 189206.
  • Guth BD, Rast G (2010). Dealing with LERG liabilities early: diverse approaches to an important goal in drug development. Br J Pharmacol 159: 2224.
  • Guth BD, Germeyer S, Kolb W, Markert M (2004). Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods 49: 159169.
  • Hammond TG, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Redfern WS et al. (2001). Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 49: 741750.
  • Harmer AR, Abi-Gerges N, Easter A, Woods A, Lawrence CL, Small BG et al. (2008). Optimisation and validation of a medium-throughput electrophysiology-based hNav1.5 assay using IonWorkstrade mark. J Pharmacol Toxicol Methods 57: 3041.
  • Haushalter TM, Friedrichs GS, Reynolds DL, Barecki-Roach M, Pastino G, Hayes R et al. (2008). The cardiovascular and pharmacokinetic profile of dofetilide in conscious telemetered beagle dogs and cynomolgus monkeys. Br J Pharmacol 154: 14571464.
  • van der Heyden MA, Smits ME, Vos MA (2008). Drugs and trafficking of ion channels: a new pro-arrhythmic threat on the horizon? Br J Pharmacol 153: 406409.
  • Hondeghem LM, Snyders DJ (1990). Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81: 686690.
  • Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN (2005). A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther 77: 572582.
  • Kang J, Wang L, Chen XL, Triggle DJ, Rampe D (2001). Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 59: 122126.
  • Kuryshev YA, Ficker E, Wang L, Hawryluk P, Dennis AT, Wible BA et al. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther 312: 316323.
  • Lawrence CL, Pollard CE, Hammond TG, Valentin JP (2008). In vitro models of proarrhythmia. Br J Pharmacol 154: 15161522.
  • Lu HR, Vlaminckx E, Hermans AN, Rohrbacher J, Van Ammel K, Towart R et al. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br J Pharmacol 154: 14271438.
  • McMahon N, Pollard CE, Hammond TG, Valentin J-P (2007). Cardiovascular safety pharmacology. In: SietsemaWK, SchwenR (eds). Nonclinical Drug Safety Assessment: Practical Considerations for Successful Registration. FDA News: Falls Chuch, pp 87123.
  • Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43: 369379.
  • Mitcheson JS, Perry MD (2003). Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 6: 667674.
  • Pollard CE, Valentin JP, Hammond TG (2008). Strategies to reduce the risk of drug-induced QT interval prolongation: a pharmaceutical company perspective. Br J Pharmacol 154: 15381543.
  • Priest BT, Swensen AM, McManus OB (2007). Automated electrophysiology in drug discovery. Curr Pharm Des 13: 23252337.
  • Pugsley MK, Authier S, Curtis MJ (2008). Principles of safety pharmacology. Br J Pharmacol 154: 13821399.
  • Rampe D, Wible B, Brown AM, Dage RC (1993). Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 44: 12401245.
  • Rampe D, Roy ML, Dennis A, Brown AM (1997). A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417: 2832.
  • Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 3245.
  • Rezazadeh S, Hesketh JC, Fedida D (2004). Rb+ flux through hERG channels affects the potency of channel blocking drugs: correlation with data obtained using a high-throughput Rb+ efflux assay. J Biomol Screen 9: 588597.
  • Roden DM, George AL Jr (1996). The cardiac ion channels: relevance to management of arrhythmias. Annu Rev Med 47: 135148.
  • Schroeder K, Neagle B, Trezise DJ, Worley J (2003). Ionworks HT: a new high-throughput electrophysiology measurement platform. J Biomol Screen 8: 5064.
  • Shah RR (2006). Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7: 889908.
  • Shah RR, Morganroth J (2008). Evaluating the QT-Liability of a Drug during its Development. Pharm Med 22 (3): 151164.
  • Suessbrich H, Waldegger S, Lang F, Busch AE (1996). Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 385: 7780.
  • Tattersall ML, Dymond M, Hammond T, Valentin JP (2005). Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. J Pharmacol Toxicol Methods.
  • Wallis RM (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. Br J Pharmacol 159: 115121.
  • Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 5: 116126.
  • Wible BA, Hawryluk P, Ficker E, Kuryshev YA, Kirsch G, Brown AM (2005). HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk. J Pharmacol Toxicol Methods 52: 136145.
  • Yan GX, Antzelevitch C (1998). Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98: 19281936.
  • Yang T, Roden DM (1996). Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 93: 407411.
  • Zehelein J, Zhang W, Koenen M, Graf M, Heinemann SH, Katus HA (2001). Molecular cloning and expression of cERG, the ether a go-go-related gene from canine myocardium. Pflugers Arch 442: 188191.